PDS Biotechnology Corporation has announced a significant financial boost following the exercise of warrants by NantWorks. The exercise, which involves an aggregate of 17,699,115 shares of common stock, has generated approximately $3.9 million in gross proceeds for the company. This development is crucial as it supports PDS Biotechnology's ongoing efforts to advance its cancer therapies, particularly in the area of targeted immunotherapy.
The warrant exercise was officially disclosed in a recent filing with the SEC, dated November 10, 2026. The funds raised will be utilized to further the development of PDS0301, aimed at treating metastatic colorectal cancer, and to enhance the company’s partnership strategy for PDS0101, among other corporate purposes.
Background
PDS Biotechnology Corp, based in Princeton, New Jersey, operates within the pharmaceutical preparations sector, specifically focusing on developing targeted immunotherapies for cancer. The company trades on the Nasdaq under the ticker symbol PDSB. Recent filings indicate a series of strategic moves, including a private placement in September 2026 that netted approximately $11.3 million, further solidifying its financial foundation.
What the Filing Says
The SEC filing reveals that NantWorks exercised its common stock warrants at an exercise price of $0.22 per share. The filing states, "The gross proceeds to the Company from the exercise of existing warrants were approximately $3.9 million." This financial influx is expected to bolster PDS Biotechnology’s clinical programs and operational strategies.
Impact
This warrant exercise is likely to have a positive impact on various stakeholders, including investors and patients awaiting innovative cancer therapies. The funds will not only enhance PDS Biotechnology’s research capabilities but also reinforce its position in the competitive pharmaceutical landscape, where numerous companies are vying for advancements in immunotherapy.
What's Next
Details on subsequent actions following this filing were not available. However, the company is expected to utilize the newly acquired funds to propel its clinical trials and partnership initiatives.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










